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Abstract
Premature infants represent one of the groups with increased risk for metabolic syndrome.
Our study is the first one to evaluate irisin and visfatin levels, associated with the metabolic
syndrome, both in blood of preterm and full-term infants, as well as in the breastmilk of their
mothers. A total of 72 newborns was enrolled in the study, including 53 very low birth weight
preterm infants and a control group of 19 term infants. The levels of irisin and visfatin were
determined by a commercial enzyme-linked immunoabsorbent assay both in the baby
serum and maternal milk twice, first during the 1st week of life and then 4 weeks later. Pre-
term infants had significantly lower serum irisin levels compared to the term infants. Overall,
serum irisin level during the 1st week of life was positively correlated with several anthropo-
metric measurements at birth, as well as during 5th weeks of age. In contrast, serum visfatin
levels during 5th week of life were negatively correlated with z-scores of birth weight, weight
and head circumference during 5th week of age. We found a strong negative correlation
between serum irisin and serum visfatin levels at both analyzed time points. The level of
milk visfatin was significantly higher in the mothers of the preterm group during 5th week of
life. In conclusion, our results provide further evidence that irisin and visfatin may play physi-
ologic roles in development of both preterm and full-term newborns during their first month
after birth. Observed differences in irisin and visfatin serum and breastmilk concentrations
during the earliest stages of life may contribute to development of catch up growth, but also,
they might eventually lead to a higher risk for metabolic syndrome in prematurely born chil-
dren in later years.
Introduction
Preterm very low birth weight (VLBW) neonates are at a higher risk of metabolic syndrome
later in life. Preterm infants at term equivalent age are lighter, shorter, have higher percentage
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of total fat mass and lower fat free mass [1], [2]. At 1–3 years, they exhibit excessive weight-
for-length z-scores and elevated systolic blood pressure [3], [4]. Barker et al. shows a significant
relationship between low birth weight, low weight at 1 year of life, catch up growth in child-
hood on one hand, and increased risk of adverse outcomes such as diabetes type 2, obesity, car-
diovascular diseases on the other [5]. Numerous reports emphasize the importance of
perinatal nutritional status for the survival of VLBW infants. It appears that childhood nutri-
tion is critical in a regulation of lifelong appetite since it may affect some of the feeding regula-
tory mechanisms both in the central nervous system and peripheral tissues. Early life nutrition
plays an important role in long-term appetite control. It is involved in the lifelong program-
ming of feeding regulatory mechanisms in the central nervous system, including the ones
mediated by factors from the peripheral tissues [6]. Early feeding model affects growth and
body composition in the future [7].
Visfatin, originally identified as pre-B-cell colony-enhancing factor (PBEF), is a
491-amino-acid protein with a molecular weight 52 kDa [8]. It is produced and secreted from
the visceral adipose tissue, which increase is strongly associated with the metabolic syndrome
[9]. Visfatin is an adipokine that affects a number of metabolic and immune- processes,
including regulation of white adipose tissue (WAT). It is up-regulated in obesity and insulin
resistance [10], it exerts insulin like effects in various tissues [9]. Fukuhara et al. demonstrates
a correlation between plasma visfatin concentrations and the amount of visceral fat [9]. There
are studies that confirm significantly increased serum visfatin levels in neonates with intrauter-
ine growth retardation (IUGR) and extremely low birth weight (ELBW) [11], [12].
Irisin is a newly discovered myokine with anti-obesity properties. Irisin regulates body
energy expenditure by turning white adipose tissue into brown-like adipose tissue [13]. It is
regarded as a potential biomarker of metabolic syndrome and obesity. In clinical settings,
patients with type 2 diabetes mellitus have lower levels of irisin compared to healthy controls
[14], [15]. Moreover, irisin’s precursor, fibronectin type III domain-containing protein 5
(FNDC5), is decreased in patients with obesity [16].
Visfatin and irisin are also present in human milk. It is suggested that autonomous produc-
tion by breast tissue is the source of those hormones in the breast milk. It appears that these
bioactive peptides found in the breast milk are important for growth, energy regulation and
maturation of the gastrointestinal system in neonates [17], [18], [19]. The physiologic role of
irisin and visfatin in neonates, especially in VLBW infants, remains to be studied. The goal of
our prospective study was to analyze concentrations of irisin and visfatin both in the VLBW
and full-term infants’ serum, as well as their mothers’ breast milk. We also examined an associ-
ation between blood irisin and visfatin levels and selected anthropometric parameters.
Materials and methods
Study design and area
The prospective observational study included newborns and their lactating mothers admitted
to the Neonatal Intensive Care Unit, Department of Paediatrics, Jagiellonian University Medi-
cal College, Krakow, Poland, between February 2014 and November 2016. The study protocol
was approved by the Jagiellonian University Medical College Ethical Committee (issue No
KBET/58/B/2013 from 4.04.2013). Written and informed consents were obtained from the
parents. Study was sponsored by NUTRICIA Foundation (RG 7/2013).
Inclusion criteria
Study group consisted of preterm newborns with birth weight between 1000 -1500g and term
newborns with birth weight between 2500g - 4000g. All the neonates admitted to the hospital
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who fulfilled inclusion criteria (admission before 5th day of life, feeding started within first 48
hours of life) were included in the study. Only 2 children were not enrolled due to lack of the
parental consent. Full term newborns were admitted to the NICU due to moderate ailments
that frequently occurred in the neonatal period (e.g. severe hyperbilirubinemia, transient
tachypnoea of newborn or other adaptation disorders), which did not affect proper physical
development in researcher’s opinion. A formal sample size calculation was not performed to
allow a realization of a hypothesis generating study. The approximate sample size was based
on the calculations from the previous publication [20]. The power analysis [21] indicated that
with 53 experimental subjects and 19 control subjects, the estimated power of the study to vali-
date the measured means difference of the fat mass at the level of 100g was 0.8 (p = 0.05).
Using mentioned above method we performed the power calculation for the present study.
The estimated detectable true difference between the means of serum irisin concentration was
0.6 ug/ml, and between the means of serum visfatin concentration was 1.6 ng/ml.
Exclusion criteria
Exclusion criteria for all the groups were: severe congenital malformations, chromosomal
aberrations, asphyxia (5th minute Apgar Score < 3 points), intraventricular hemorrhage grade
IV, and severe infections (early onset neonatal sepsis, meningitis).
All infants required parenteral infusion of glucose, lipids and amino acids from the time of
their admission until their oral feeding reached adequate volumes. All infants started oral feed-
ing within 24–48 hours with either breast milk, which was supplemented with a standard dose
of human milk fortifier when the feeding portion exceeded 140 mls/kg/day (Bebilon HMF,
Nutricia), or a formula specially adapted for the preterm infant (PreNAN, Nestle, or Bebilon
Nenatal, Nutricia). The infants were fed by nipples or nasogastric tubes. Each mother was
encouraged to provide milk for her own infant; due to lack of availability we could not use
human milk from a milk bank.
Anthropometric measurements
Anthropometric measurements such as weight, length, and head circumference were collected
twice: at birth, and then 4 weeks later (during 5th week of life). All infants were weighed naked
to the nearest 10g on an electronic baby scale (RADWAG 2006). Crown-heel length and occi-
pito-frontal circumference were measured to the nearest 0.5cm by a standard measuring tape.
A single investigator made all the measurements. Anthropometric parameters Z-score were
obtained using a reference by Fenton et al. [22]. The BIA analysis to determine body composi-
tion was carried out either at estimated time of birth in the VLBW groups or during the 1st
week of life in the control group. The data regarding body composition were presented in the
results section. Detailed description of BIA analysis was provided elsewhere [20].
Hormone assays
The samples were collected twice: during the 1st week of life, and then 4 weeks later (5th week
of life). We used test tubes with aprotinin, a protease inhibitor (Becton Dickinson Vacutainer)
to collect blood and milk samples. Blood samples were transferred immediately after drawing
to the Department of Clinical Biochemistry, Institute of Pediatrics, Jagiellonian University
Medical College, Krakow, Poland and centrifuged. The supernatant plasma was separated and
immediately stored in a deep freezer (-80˚C) until assay. Milk samples were transferred to the
above laboratory and immediately stored in a deep freezer (-80˚C) until assay.
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Levels of irisin were measured by an ELISA commercial kit (RAG018R, BioVendor, Brno,
Czech Republic). The minimum detectable concentration, intraassay and interassay coeffi-
cients of variation were 0.001μg/ml, 5–8%, 8–10%, respectively.
Levels of visfatin were measured by an ELISA commercial kit (RAG004R, BioVendor,
Brno, Czech Republic). The minimum detectable concentration, intraassay and interassay
coefficients of variation were 0.003μg/ml, 2.5–9%, 4.66–7.24%, respectively.
Statistical analysis
JMP 13.1.0 software (SAS Institute, Cary, North Carolina) was used for statistical analysis.
Demographic and clinical data comparisons between the study and control groups were per-
formed using Student’s t-test or chi- square test, depending on the data character and their dis-
tribution. The data were expressed as arithmetic means ± SD. The detected differences were
considered statistically significant in case of p<0.05. Correlations between hormone levels and
anthropometric measurements were analysed using Spearman’s test.
Results
The baseline characteristics of the study population were summarized in Table 1. The baseline
characteristics of the patients’ mothers, including possible causes of preterm birth were shown
in Table 2. We found no differences between mothers of VLBW and full-term infants, except
thyroid disease frequency that was significantly higher in the mothers of preterm babies.
Preterm VLBW infants at their expected time of birth had higher fat mass and percentage
amount of fat mass, whereas their total body water, percentage amount of TBW and percent-
age amount of FFM were lower compared to the full-term control group during their 1st week
of life (Table 3).
Table 1. Baseline characteristics of the study and control populations. Data are presented as mean with standard deviation (SD), or number and fraction of patients
(%) as appropriate.
Study group VLBW infants (n = 53) Control group term infants (n = 19) p-value
Gestational age [weeks], mean (SD) 30 (2.03) 39 (1.32) <0.00011
Birth weight [g], mean (SD) 1257.0 (161.8) 3396.4 (421.6) <0.00011
Birth weight z-score, mean (SD) -0.28 (0.94) 0.1 (0.89) 0.121
Birth length [cm], mean (SD) 40.02 (2.6) 53.5 (3.63) <0.00011
Birth length z-score, mean (SD) 0.48 (0.95) 1.99 (0.92) <0.00011
Birth head circumference [cm], mean (SD) 27.14 (1.59) 34.4 (1.26) <0.00011
Birth head circumference z-score, mean (SD) -0.05 (1.22) 0.05 (1.07) 0.7531
Weight at 4th weeks [g], mean (SD) 1707.27 (277.22) 4026 (461.31) <0.00011
Weight at 4th weeks z-score, mean (SD) -0.93 (0.82) 1.32 (0.83) <0.00011
Length at 4th weeks [cm], mean (SD) 43.71 (2.41) 55.8 (3.19) <0.00011
Length at 4th weeks z-score, mean (SD) 0.07 (0.90) 3.19 (1.69) <0.00011
Head circumference at 4th weeks [cm], mean (SD) 29.37 (1.50) 36.63 (1.40) <0.00011
Head circumference at 4th weeks z-score, mean (SD) -0.65 (0.79) 1.79 (1.08) <0.00011
Male gender 28 (53%) 13 (68%) 0.2392
Vaginal delivery 10 (19%) 7 (37%) 0.1132
Small for Gestational Age 6 (11%) 0 (0%) 0.1262
P-value was significant in case of p<0.05.
1—Student’s t-test
2—chi-square test.
https://doi.org/10.1371/journal.pone.0204835.t001
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Preterm VLBW infants had significantly lower serum irisin levels compared to the term
infants both during the 1st and 5th week of life. Milk visfatin level in the study group increased
over the span of 4 weeks, and it was significantly higher in the 5th week of life. The level of milk
visfatin was significantly higher in the mothers of the preterm group during 5th week of life.
There were no other significant differences between serum visfatin levels, milk visfatin and
milk irisin levels in both time points (Figs 1 and 2).
Serum irisin level during the 1st week of life was positively correlated with several anthropo-
metric parameters including birth weight, birth length, head circumference at birth, weight
and head circumference at 5 weeks. Serum irisin levels during the 1st week of life were posi-
tively correlated with their concentration after 4 weeks. Serum visfatin levels in the second
sampling, at 5th week of life, were negatively correlated with z-scores for birth weight, length
and head circumference. Interestingly, we found a strong negative correlation between serum
irisin and serum visfatin during the 1st week of life, which persisted over the following 4 weeks
of the study (Table 4).
Table 2. Maternal characteristics of the study population. Data are presented as mean with standard deviation
(SD), or number and fraction of patients (%) as appropriate.
Study group VLBW infants
(n = 53)
Control group term infants
(n = 19)
p
Maternal age [years], mean (SD) 29.15 (5.49) 30.84 (5.11) 0.23351
Gestational weight gain [kg], mean
(SD)
9.58 (5.50) 12.18 (4.86) 0.06431
Gestation 0.31552
1 26 (49%) 5 (26%)
2 15 (28%) 10 (53%)
3 12 (23%) 4 (21%)
Pregnancy complications
Hypertension 14 (26.4%) 2 (10.5%) 0.13012
Diabetes 4 (7.5%) 1 (5.3%) 0.71562
Thyroid disease 6 (11.3%) 7 (36.8%) 0.01842
P-value was significant in case of p<0.05.
1 –two-sided T-test
2—chi-square test.
https://doi.org/10.1371/journal.pone.0204835.t002
Table 3. Body composition of the study population presented as mean values and SD.
Study group VLBW infants (n = 53) Control group term infants (n = 19) P
TBW [kg] 2.57 (0.46) 3.15(0.69) 0.00171
TBW % 72.05 (7.71) 92.78 (14.16) 0.00011
FFM [kg] 2.99 (0.47) 2.88 (0.35) 0.36852
FFM % 83.71 (1.67) 85.49 (1.31) 0.00012
FM [kg] 0.59 (0.16) 0.49 (0.1) 0.02751
FM % 16.29 (1.67) 14.51 (1.31) 0.00012
P-value was significant in case of p<0.05.
1 –Wilcoxon/Kruskal-Wallis test
2 –two-sided T-test.
TBW- total body water, TBW %- percentage amount of total body water, FFM- fat free mass, FFM %- percentage
amount of fat free mass, FM- fat mass, FM %- percentage amount of fat mass.
https://doi.org/10.1371/journal.pone.0204835.t003
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Milk irisin during the 1st week of life was positively correlated with milk irisin level 4 weeks
later. Milk visfatin during the 1st week of life was also positively correlated with milk visfatin
level at the second time point of the study (Table 4).
We found some differences in the levels of irisin and visfatin in preterm babies’ moth-
ers between the ones with and without pregnancy complications (data not shown). Moth-
ers diagnosed with hypertension had significantly higher breastmilk irisin levels than
mothers without hypertension during 5th week of infants’ life. In case of diabetes mellitus,
the mothers presented significantly lower serum visfatin levels during 1st week after birth
and significantly higher visfatin levels 4 weeks later compared to the mothers without dia-
betes mellitus.
Discussion
Our prospective cohort study shows that blood irisin levels are positively correlated with
weight, length and head circumference of a child at birth, as well as with his weight and head
circumference 4 weeks later. It has been reported that cord blood irisin levels are positively
correlated with birth weight [23], [24], birth weight Z-scores and gestational age [25]. Further,
irisin level in the umbilical artery is positively correlated with fetal weight and fetal abdominal
circumference as measured by ultrasonography [26]. Our findings support and expand the
above observations, since the samples were collected from the newborns during their 1st and
5th week of life. Our study confirms that VLBW preterm infants present significantly lower
serum irisin levels compared to the term infants during the 1st and 5th week of life, and there is
Fig 1. Comparison of milk and serum irisin concentrations in the groups of full-term and preterm newborns.
Data are presented as median and interquartile range, P-values for U Mann-Whitney test.
https://doi.org/10.1371/journal.pone.0204835.g001
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a positive correlation between first and second assessment. Decreased irisin might result in
smaller amount of fat free mass and higher fat mass observed in VLBW group at estimated
Fig 2. Comparison of milk and serum visfatin concentrations in the groups of full-term and preterm newborns. Data
are presented as median and interquartile range, P-value for U Mann-Whitney test.
https://doi.org/10.1371/journal.pone.0204835.g002
Table 4. Spearman’s correlation between serum and milk irisin and visfatin levels and anthropometric parameters in the two tested groups.
Variable by Variable Spearman ρ Prob>|ρ|
Serum irisin levels during 1st week (μg/ml) Birth weight (g) 0.3768 0.0011
Birth length (cm) 0.3300 0.0046
Birth head circumference (cm) 0.2562 0.0298
Weight at 4th week (g) 0.3160 0.0110
Head circumference at 4th weeks (cm) 0.2690 0.0316
Serum irisin levels during 5th week (μg/ml) Serum irisin levels during 1st week 0.4293 0.0005
Serum visfatin levels during 1st week (ng/ml) Serum irisin levels during 1st week -0.3612 0.0018
Serum visfatin levels during 5th week (ng/ml) Serum irisin levels during 5th week -0.5318 <0.0001
Serum visfatin levels during 5th week (ng/ml) Birth weight z-score -0.2576 0.0433
Weight at 4th week z-score -0.3071 0.0152
Milk irisin levels during 5th week (μg/ml) Milk irisin levels during 1st week 0.5664 0.0006
Milk visfatin levels during 5th week (ng/ml) Milk visfatin levels during 1st week 0.7071 <0.0001
https://doi.org/10.1371/journal.pone.0204835.t004
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time of birth. To our best knowledge this is the first report of irisin blood levels in VLBW new-
borns. Studies from the literature show that infants born as small for gestational age (SGA)
present decreased levels of irisin in comparison to their appropriate for gestational age (AGA)
counterparts [23], [24], [25], which might result from their much smaller muscular mass and
reduced brown adipose tissue [24], [25], [27]. Previous studies in full term infants demonstrate
irisin levels overall higher compared to the findings in our study [24]. We suppose that we
detect lower irisin levels since our blood samples are collected directly from the infants, in con-
trast to the previous studies that presented irisin analyses in the umbilical blood most probably
affected by the maternal serum irisin. We do not observe any significant differences in serum
visfatin levels between VLBW and term newborns during their 1st week and 5th week of life.
Our findings are similar to those observed by Cekmez et al, [12], however they contradict
other reports demonstrating lower serum visfatin in VLBW infants compared to the full-term
infants [11], [28] and adults [29]. In our study serum visfatin levels during 5th week of life are
negatively correlated with the birth weight z-score, weight z-score at 5 weeks, and head cir-
cumference z-score at 5 weeks in contrast to some previous studies [28]. We assume that the
observed relative decrease of visfatin might be associated with the rapid catch-up growth
observed in VLBW and ELBW newborns [30], [31].
We find a strong negative correlation between serum irisin and serum visfatin levels during
1st as well as 5th week of life. The above hormones present antagonizing actions, since irisin
shows anti-obesity properties while visfatin increases in obesity. It is possible that if one of
these hormone increases, then the other one is down-regulated, although the exact molecular
mechanisms remain to be discovered.
There is a number of reports demonstrating that human milk contains a variety of hor-
mones which regulate body weight and composition [17], [32], [33], [34], [35]. One of them is
irisin, however its role in regulation of newborn development is to be discovered. Aydin et al.
find that levels of irisin are highest in colostrum, then decrease in transitional and mature milk
from healthy women. It is different in gestational diabetes, where irisin is significantly lower in
the colostrum and transitional milk than in the mature milk [18]. The highest irisin concentra-
tion is found in maternal blood, even compared to colostrum as reported by Brianna and col-
leagues [36]. Our study is the first one to assess irisin and visfatin levels in breast milk of
mothers of VLBW infants. We find no differences between irisin levels measured in milk sam-
ples from mothers of VLBW infants compared to samples from mothers of term newborns.
We hypothesize that breast milk irisin levels may affect postnatal adaptation with respect to
thermoregulation, glucose metabolism and neonatal homeostasis, which further supports
introduction of early breastfeeding.
In the early studies visfatin was identified in the mammalian epithelial cells in the mam-
mary gland and milk, later confirmed in the breast milk in humans, reaching significantly
higher concentrations than in the maternal serum [37][17]. Moreover, visfatin concentration
in colostrum could be used for prediction of the subsequent weight development of the infant,
demonstrated as less or more severe weight loss during the first 3 days of life [17]. This obser-
vation strongly suggests that increased concentration of visfatin in the human milk plays a pro-
tects of against a weight loss during its first days after birth. Bienertová-Vašků et al. speculate
that the above effects might result from breast milk visfatin- mediated insulin-like effect on
child’s adipose tissue [17]. In contrast to the previous studies, we found increased visfatin lev-
els in breast milk during 5th week postpartum in VLBW group. Since VLBW infants are much
more susceptible to severe weight loss after birth, we believe that significantly higher visfatin
levels in their mother’s milk may represent some additional, natural protection against it.
In conclusion, the results of our study suggest that irisin and visfatin may represent a poten-
tial link between VLBW status at birth and later metabolic syndrome; however, a direct causal
Irisin and visfatin levels in preterm newborns
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relationship cannot yet be confirmed. Such a hypothesis needs to be addressed in a longitudi-
nal study of irisin levels, postnatal weight gain and their association with obesity and metabolic
syndrome in the future.
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glu OM, Sarici SU. Adiponectin and visfatin levels in extremely low birth weight infants; they are also at
risk for insulin resistance. Eur Rev Med Pharmacol Sci. 2013 Feb; 17(4):501–6. PMID: 23467949
13. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long
JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM. A PGC1-α-
dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature.
2012 Jan 11; 481(7382):463–8. https://doi.org/10.1038/nature10777 PMID: 22237023
14. Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, Kim JG, Lee IK, Park KG. Serum irisin levels in
new-onset type 2 diabetes. Diabetes Res Clin Pract. 2013 Apr; 100(1):96–101. https://doi.org/10.1016/
j.diabres.2013.01.007 PMID: 23369227
15. Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, Tavintharan S, Sum CF, Lim SC. Lower circulating
irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013 Jul-Aug; 27(4):365–9.
https://doi.org/10.1016/j.jdiacomp.2013.03.002 PMID: 23619195
16. Al-Daghri NM, Mohammed AK, Al-Attas OS, Amer OE, Clerici M, Alenad A, Alokail MS. SNPs in
FNDC5 (irisin) are associated with obesity and modulation of glucose and lipid metabolism in Saudi sub-
jects. Lipids Health Dis. 2016 Mar 11; 15:54. https://doi.org/10.1186/s12944-016-0224-5 PMID:
26968837
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